David Melamed, PhD,  —

Following yearlong advocacy efforts, the triple-combination therapy Trikafta is expected to soon come up for approval before Health Canada, the country’s health regulatory agency, the non-profit patient group Cystic Fibrosis Canada has announced on its website. Vertex Pharmaceuticals, which developed and markets Trikafta, its newest modulator therapy for cystic fibrosis and…

The Cystic Fibrosis Foundation (CFF) has awarded nearly $15 million to 33 organizations that are researching how to improve outcomes for cystic fibrosis (CF) patients who are battling infections. The awards fall under the CFF’s Infection Research Initiative, a large-scale effort to provide $100 million in funding…

AzurRx BioPharma has launched a Phase 2b clinical trial investigating its MS1819 as a potential treatment for exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The first patient has now been screened in the OPTION 2 trial (NCT04375878), which has opened at three…

A potential way of killing persistent bacterial infections like those common to people with cystic fibrosis (CF) — using nutrient channels that may exist within bacterial communities to carry antibiotics — is suggested by a research team at the University of Strathclyde in Glasgow. Their study, “…

Investigational treatment Encala (Lym-X-Sorb) is safe, well tolerated, and increased dietary fat absorption in patients with cystic fibrosis (CF) and pancreatic insufficiency, according to an analysis from a Phase 2 clinical trial. Findings from the analysis were reported in the study, “Improved residual fat malabsorption…

Researchers identified a biochemical mechanism that regulates the thickness of mucus, and could serve as a target of new treatments for chronic respiratory illnesses that include cystic fibrosis (CF). The study, “Trefoil factors share a lectin activity that defines their role in mucus,” was published in the journal …

Translate Bio‘s therapy MRT5005 has been given a rare pediatric disease designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic fibrosis in children, while its ongoing clinical trial investigating the therapy in adult patients faces delays due to the COVID-19…

The non-profit organization Claire’s Place Foundation has launched a donation-based COVID-19 Emergency Fund to support the cystic fibrosis (CF) community by raising funds to provide patients and their families with groceries, supplies, and medications during the outbreak. The fund will be available for people with CF and…

Prolonged use of the antibiotic azithromycin resulted in a 37% slower rate of lung function decline in cystic fibrosis (CF) patients with persistent Pseudomonas aeruginosa infection over a three-year period, a study found. The study, “Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic…

With the outbreak of coronavirus (COVID-19) affecting thousands of people around the world, individuals with respiratory conditions such as cystic fibrosis (CF) need to take precautions, according to medical expert Richard K. Mathis, MD. Mathis is a board member of Claire’s Place Foundation, a nonprofit organization that…